Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watche...
24 November 2021 Regional News Aimovig | Amgen Repatha
Continue Reading →
Regional News

Novartis may have a buyer for $21B generics unit Sandoz

Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from Sandoz. Swedish-...
24 November 2021 Regional News divestment | generics
Continue Reading →
Regional News

Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nears

About two decades ago, Novartis transformed leukemia treatment with the introduction of Gleevec. Now, the Swiss pharma has ushered a third-generation therapy targeted...
2 November 2021 Regional News FDA | Gleevec
Continue Reading →
Regional News

Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure

Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer (NSCLC)? After two pivotal trial failures, the answer seems to be ...
26 October 2021 Regional News Ilaris | lung cancer
Continue Reading →
Regional News

Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team

Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international specialty care t...
13 October 2021 Regional News drugmaker | Ipsen
Continue Reading →
Regional News

Viatris to close former Novartis site in California in January, lay off 75

Viatris has been busy with cost cuts over the last year, including shuttering a plant in West Virginia that had served as a staple of its community. Now, a former Nov...
13 October 2021 Regional News California | Mylan
Continue Reading →
Regional News

Gilead’s Kite enters leukemia with Tecartus FDA approval, overlapping Novartis’ CAR-T rival Kymriah

Gilead Sciences’ Kite Pharma has expanded its second CAR-T cell therapy, Tecartus, into a leukemia market that overlaps a Novartis territory for Kymirah. The FDA cle...
6 October 2021 Regional News CAR-T cell therapy | Gilead Sciences’ Kite Pharma
Continue Reading →
Regional News

Novartis, determined to dethrone Pfizer, will launch bold Kisqali-Ibrance head-to-head trial in breast cancer

Despite two life extension wins, Novartis still finds it tough to convince doctors to use its breast cancer drug Kisqali over Pfizer’s first-to-market Ibrance. Now, w...
22 September 2021 Regional News breast cancer | Ibrance
Continue Reading →
Regional News

Novartis’ Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded

Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb r...
25 August 2021 Regional News Bristol Myers | CAR T
Continue Reading →
Europe

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible - Using patients' self-recorded meas...
25 April 2018 Europe | North America app | FocalView
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte